近日,研究人员在Signal Transduction and Targeted Therapy上发表论文,报道了CPT1A在介导肺癌干细胞(LCSCs)铁死亡耐受中的作用,具有成为肺癌免疫治疗新靶点的潜力。 研究人员发现CPT1A是脂肪酸氧化的关键限速酶,通过左旋肉碱,驱动肿瘤相关巨噬...
for advanced non-small cell lung cancer(NSCLC)is chemotherapy.In recent years,with the rapid development of molecular pathology,we have a deeper understanding of the underlying pathological mechanism and heterogeneity of lung cancer,especially NSCLC.Molecular targeted therapy is more accurate because of ...
An analysis of 43 KRAS mutant NSCLC patients who were enrolled in the BATTLE-1 (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial determined that KRAS mutation variants G12C and G12V were significantly associated with worse median PFS compared to other ...
lennium.TargettherapythatisavailableforthetreatmentofNSCLCincludesepi- dermalgrowthfactorreceptor-tyrosinekinaseinhibitor(EGFR-TKI)and anti-angiogenesis.AvailabledrugsthathadbeenapprovedforuseinNSCLCin TaiwanincludedgefitinibanderlotinibasEGFR-TKIs,andbevacizumabas anti-angiogenesis.Mediansurvivalwas5.6monthsinpatientsrece...
Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Treatment outcomes in advanced or metastatic non-small-cell lung cancer (NSCLC) remain unsatisfactory, with low long-term survival rates. Palliative chemot... F Janku,DJ Stewart,R Kurzrock - 《Nature Reviews Clinical ...
1. Basic and Clinical Practice of Molecular Target Therapy for Lung Cancers Objective: To evaluate the clinical application potentiality of PCR-single strand conformation polymorphism (PCR-SSCP)used to screen EGFR mutations in non-small cell lung cancer(NSCLC). Methods: Certain NSCLC specimens were ...
We first examined the potential roles of thrombin and PAR-1 in regulating the formation of VM in NSCLC. We evaluated the effects of combination therapy with DTIP and gefitinib in NSCLC. Thrombin may be a potential target for future anticancer therapies and combination therapy with direct thrombin...
[90,91]. In a phase II trial, the treatment with lapatinib did not show significant efficacy in inducing tumor regression for non-small cell lung cancer (NSCLC) in 75 patients studied [92]. On the other, lapatinib therapy is associated with a significant reduction in various forms of pain...
On early stage NSCLC CTONG initiated neo-adjuvant and adjuvant target therapy for resectable NSCLC based EGFR mutation. On advanced stage there is a head to head to comparing gefitinib with ... Y. Wu - 《Annals of Oncology》 被引量: 0发表: 0年 Biomarkers for lung cancer: Clinical uses ...
Small cell lung cancer(SCLC) is an aggressive malignancy distinct from non-small cell lung cancer(NSCLC) in its metastatic potential and treatment response.Improvement in the clinical outcome of lung cancer is more likely to be associated with the molecular targeted therapy based on its pathogenesis...